Google translate of the above signing ceremony and presentation;...

Google translate of the above signing ceremony and presentation;

Ian Fraser, the father of cervical cancer vaccine, has set up a research and development team in China.
2018-09-22 Source: Health Times Network
(Health Times reporter Wu Wei / Wen Cao Cheng / map )

On September 22, Health Times reporter learned at the 2018 International Biotherapy Summit Forum that the inventor of cervical cancer vaccine, Ian Fraser, will bring cervical cancer therapeutic vaccination The class R&D team settled in Shenzhen, China!

Ian Fraser: Shenzhen will become the "main battlefield" for cervical cancer.

The proportion of cancers caused by infection is greater than 20% in all cancers. And papillomavirus (HPV)-related cancer kills 400,000 people worldwide each year. Last year, the four-valent HPV vaccine that can prevent cervical cancer was approved for listing in mainland China. One year later, it was "a difficult to find a seedling."

As the father of the cervical cancer vaccine, the president of the forum, Academician Ian Fraser, described the future research plan: "I will lead the research and development team, join the R&D team in Shenzhen, and cooperate in the research and development of HPV therapeutic vaccine. And strive to carry out a phase of clinical trials during the year. "Fraser said that Shenzhen is an ideal place for research and development of translational medicine: "There are quality hospitals and universities here, which are all favorable factors for the development of translational medicine."

At the forum, Dr. Fraser and Chairman of the company, Mr. Zhang Lishan, the main shareholder of Admedus Co., Ltd., and Mr. Wayne Paterson, the president of Admedus Co., Ltd., conducted the medical treatment. The signing ceremony of the shareholders of the company marks the official launch of the HPV therapeutic vaccine research and development project in China.

As another heavyweight expert in this forum, Professor Wu Peihong, the director of the Imaging and Minimally Invasive Intervention Center of the Affiliated Tumor Hospital of Sun Yat-sen University, led his medical research and development team at Zhongshan Medical University to open the first cell immune technology and minimally invasive technology to treat cancer in China. There have been several success stories. Professor Wu Peihong said: "The constructive treatment of tumors is a humanized, rational and individualized treatment. It is to effectively protect the disease while maximally protecting the patient's physiological functions and improving immune function, maximizing protection and improvement. The quality of life of the patient."

There are 570,000 new cases of cervical cancer and 310,000 deaths every year in the world; 100,000 new cases of cervical cancer occur every year in China, and 30,000 deaths (accounting for 17.5% of global cervical cancer annual incidence, about 10% mortality), cervical cancer in China The rate is 10.6/100,000 and the mortality rate is 2.98/100,000. Huang He, deputy director of the Cancer Center of Sun Yat-sen University, shared the epidemiology of cervical cancer in China at the 2018 International Biotherapy Summit. In addition, the incidence of cervical cancer is younger, and the average age of patients with symptoms has decreased by about 5 years in the past decade. He believes that China currently has a lot of room for improvement in cervical cancer prevention.

With the theme of “Gathering Global Wisdom and Creating a New Life Story”, the forum has brought together many experts in biotherapeutics at home and abroad to share the latest research results in the field of biotherapy, discuss and gain insights into industrial cooperation, with a view to promoting the most cutting-edge in this field. Technological development.
(Editor: Wu Hao)